We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

https://www.tipranks.com/news/the-fly/sarepta-could-be-down-on-patient-death-in-fda-database-says-rbc-capital RBC Capital analyst Brian Abrahams says shares of ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...

Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target remains the same with $75.00.

Sarepta (SRPT) announced topline results from Part 2 of EMBARK, a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of Elevidys, the only approved gene therapy in ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.

Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed. Sarepta is developing gene ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. Solid Biosciences advances ...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was ...

Sarepta Therapeutics SRPT has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...